<DOC>
	<DOCNO>NCT02913066</DOCNO>
	<brief_summary>Will meet inclusion criterion patient esophageal squamous cell carcinoma , divide 2 group randomly : Experimental group : radiotherapy combine S-1 chemotherapy . Control group : radiotherapy combine S-1 chemotherapy cisplatin .</brief_summary>
	<brief_title>S-1 IMRT Versus S-1 Cisplatin Concurrent IMRT Inoperable Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description>Will meet inclusion criterion patient unresectable esophageal squamous cell carcinoma , divide 2 group randomly : Experimental group : radiotherapy combine S-1 chemotherapy ; control group : radiotherapy combine S-1 chemotherapy first 14 day 29 ~ 42 day , plus cisplatin first 1~ 4 day 29 ~ 33 day . Using IMRT radiotherapy . Two week radiotherapy finish , two cycle adjuvant chemotherapy S-1 70 mg/m2 1~ 14 day , S-1 70 mg/m2 1~ 14 day , plus cisplatin 25mg/m2 1~ 4 day , 21 day cycle . Primary Outcome Measure complete remission rate . Secondary Outcome Measures overall survival ( OS ) Progression-Free-Survival ( PFS ) toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histology cytology confirm esophageal squamous cell carcinoma . 2 . There measurable lesion RECIST standard . 3 . American Joint Committee Cancer/Union Internationale Contre le Cancer esophageal cancer staging ( Sixth Edition ) clinical stage II a~ IV B period . 4 . Age young 75 year old . 5 . Eastern Cooperative Oncology Group physical status score 0 ~ 1 . 6 . No esophageal perforation active esophageal bleeding , obvious trachea , thoracic major vascular invasion . 7 . Chest chemotherapy radiotherapy , immunotherapy biologic therapy perform . 8 . Serum hemoglobin is〈100g/L , platelet〉100 * 109/L , Absolute neutrophil count〉1.5 * 109/L . 9 . Cr≤1.25 upper normal limit CCr≥60 mL/min . 10 . Serum bilirubin ≤1.5 time upper normal limit , Aspartate transaminase ( SGOT ) Alanine aminotransferase ( SGPT ) ≤ 2.5 time upper normal limit , Alkaline phosphatase≤ 5 time upper normal limit . 11 . A history interstitial pneumonia interstitial pneumonia . 12 . FEV1＞0.8 liter . 13 . Patients family member sign formal informed consent . 1 . Prior start trial receive thoracic radiotherapy , chemotherapy surgical resection esophageal cancer . 2 . Primary lesion multifocal esophageal cancer patient , low bound esophageal primary lesion less 3cm . 3 . Patients severe cardiovascular pulmonary disease , interstitial pneumonia history interstitial pneumonia . 4 . Patients distant metastasis . 5 . There obvious esophageal ulcer , chest back moderate pain , symptom esophageal perforation . 6 . Ca n't understand test requirement , patient may comply requirement test . 7 . There malignant lesion patient , cure skin cancer ( non melanoma ) , cervical carcinoma situ malignant disease cure except 5 year . 8 . An allergic reaction know 3 4 level treatment . 9 . Had participate clinical trial past 30 day . 10 . The researcher believe obvious disease exclude study exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>